Publications

Links to all papers from the lab are organized by year of publication.

R. Schmidt^, C.C. Ward^, R. Dajani, Z. Armour-Garb, M. Ota, V. Allain, R. Hernandez, M. Layeghi, G. Xing, L. Goudy, D. Dorovskyi, C. Wang, Y.Y. Chen, C.J. Ye, B.R. Shy, L.A. Gilbert, J. Eyquem, J.K. Pritchard, S.E. Dodgson, A. Marson^ Base-editing mutagenesis maps alleles to tune human T cell functions. Nature (2023) *Equal contributions, ^Co-corresponding
‍

K. Mandal, G. Wicaksono, C. Yu, J.J. Adams, M.R. Hoopmann, W.C. Temple, A. Izgutdina, B.P. Escobar, M. Gorelik, C.H. Ihling, M.A. Nix, A. Naik, W.H. Xie, J. Hübner, L.A. Rollins, S.M. Reid, E. Ramos, C. Kasap, V. Steri, J.A.C. Serrano, F. Salangsang, P. Phojanakong, M. McMillan, V. Gavallos, A.D. Leavitt, A.C. Logan, C.M. Rooney, J. Eyquem, A. Sinz, B.J. Huang, E. Stieglitz, C.C. Smith, R.L. Moritz, S.S. Sidhu, L. Huang, A.P. Wiita. Structural surfaceomics reveals an AML-specific conformation of integrin β2 as a CAR T cellular therapy target. Nature Cancer 4, 1592–1609 (2023).
‍

C.A. Tsuchida*, N. Brandes*, R. Bueno*, M. Trinidad, T. Mazumder, B. Yu, B. Hwang, C. Chang, J. Liu, Y. Sun, C.R. Hopkins, K.R. Parker, Y. Qi, A.T. Satpathy, E.A. Stadtmauer, J.H.D. Cate, J. Eyquem, J.A. Fraietta, C.H. June, H.Y. Chang, C.J. Ye^, J.A. Doudna^. Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells. Cell 186, 4567–4582.e20 (2023). *Equal contributions, ^Co-corresponding authors
‍

F. Blaeschke, Y.Y. Chen, R. Apathy, B. Daniel, A.Y. Chen, P.A. Chen, K. Sandor, W. Zhang, Z. Li, C.T. Mowery, T.N. Yamamoto, W.A. Nyberg, A. To, R. Yu, R. Bueno, M.C. Kim, R. Schmidt, D.B. Goodman, T. Feuchtinger, J. Eyquem, C.J. Ye, J. Carnevale, A.T. Sathpathy, E. Shifrut, T.L. Roth^, A. Marson^. Modular pooled discovery of synthetic knockin sequences to program durable cell therapies. Cell 186, P4216–4234.E33 (2023). ^Co-corresponding authors
‍

Y. Wu^, Z. Huang, Y. Liu*, C.W. Yoon, K. Sun, Y. Situ, P. Ho, Z. Yuan, L. Zhu, J. Eyquem, Y. Zhao, T. Liu, G.A. Kwong, S. Chien, Y. Wang^. Spatiotemporal control of genomics and epigenomics by ultrasound. bioRxiv (2023). *Equal contributions, ^Co-corresponding authors
‍

D.V. Foss*, J.J. Muldoon*, D.N. Nguyen*, D. Carr, S.U. Sahu, J.M. Hunsinger, S.K. Wyman, N. Krishnappa, R. Mendonsa, E.V. Schanzer, B.R. Shy, V.S. Vykunta, V. Allain, Z. Li, A. Marson^, J. Eyquem^, R.C. Wilson^. Peptide-mediated delivery of CRISPR enzymes for the efficient editing of primary human lymphocytes. Nature Biomedical Engineering 7, 647–660 (2023). *Equal contributions, ^Co-corresponding authors
‍

A. Odak, H. Yuan, J. Feucht, V.A. Cantu, J. Mansilla-Soto, F. Kogel, J. Eyquem, J.K. Everett, F.D. Bushman, C. Leslie, M. Sadelain. Novel extragenic genomic safe harbors for precise therapeutic T cell engineering. Blood 141, 2698–2712 (2023).
‍

W.A. Nyberg*, J. Ark*, A. To, S. Clouden, G. Reeder, J.J. Muldoon, J.-Y. Chung, W.H. Xie, V. Allain, Z. Steinhart, C. Chang, A. Talbot, S. Kim, A. Rosales, L.P. Havlik, H. Pimentel, A. Asokan^, J. Eyquem^. An evolved AAV variant enables efficient genetic engineering of murine T cells. Cell 186, 446–460.e19 (2023). *Equal contributions, ^Co-corresponding authors

D.B. Goodman*, C.S. Azimi*, K. Kearns, A. Talbot, K. Garakani, J. Garcia, N. Patel, B. Hwang, D. Lee, E. Park, V.S. Vykunta, B.R. Shy, C.J. Ye, J. Eyquem, A. Marson, J.A. Bluestone, K.T. Roybal. Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies. Science Translational Medicine 14, eabm1463 (2022). *Equal contributions
‍

M.T. Witkowski^, S. Lee, E. Wang*, A.K. Lee, A. Talbot, C. Ma, N. Tsopoulidis, J. Brumbaugh, Y. Zhao, K.G. Roberts, S.J. Hogg, S. Nomikou, Y.E. Ghebrechristos, P. Thandapani, C.G. Mullighan, K. Hochedlinger, W. Chen, O. Abdel-Wahab, J. Eyquem, I. Aifantis^. NUDT21 limits CD19 levels through alternative mRNA polyadenylation in B cell acute lymphoblastic leukemia. Nature Immunology 23, 1424–1432 (2022). *Equal contributions, ^Co-corresponding authors
‍

J. Carnevale^, E. Shifrut^, N. Kale, W.A. Nyberg, F. Blaeschke, Y.Y. Chen, Z. Li, S.P. Bapat, M.E. Diolaiti, P. O’Leary, S. Vedova, J. Belk, B. Daniel, T.L. Roth, S. Bachl, A.A. Anido, B. Prinzing, J. Ibañez-Vega, S. Lange, D. Haydar, M. Luetke-Eversloh, M. Born-Bony, B. Hegde, S. Kogan, T. Feuchtinger, H. Okada, A.T. Satpathy, K. Shannon, S. Gottschalk, J. Eyquem^, G. Krenciute^, A. Ashworth^, A. Marson^. RASA2 ablation in T cells boosts antigen sensitivity and long-term function. Nature 609, 174–182 (2022). *Equal contributions, ^Co-corresponding authors
‍

B.R. Shy^, V.S. Vykunta, A. Ha, A. Talbot, T.L. Roth, D.N. Nguyen, W.G. Pfeifer, Y.Y. Chen, F. Blaeschke, E. Shifrut, S. Vedova, M.R. Mamedov, J.-Y. Chung, H. Li, R. Yu, D. Wu, J. Wolf, T.G. Martin, C.E. Castro, L. Ye, J.H. Esensten, J. Eyquem, A. Marson^. High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails. Nature Biotechnology 41, 521–531 (2023). *Equal contributions, ^Co-corresponding authors
‍

S.J.C. van der Stegen, P.L. Lindenbergh, R.M. Petrovic, H. Xie, M.P. Diop, V. Alexeeva, Y. Shi, J. Mansilla-Soto, M. Hamieh, J. Eyquem, A. Cabriolu, X. Wang, R. Abujarour, T. Lee, R. Clarke, B. Valamehr, M. Themeli, I. Riviere, M. Sadelain. Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells. Nature Biomedical Engineering 6, 1284–1297 (2022).
‍

I.D. Ferguson, B. Patiño-Escobar, S.T. Tuomivaara, Y.-H.T. Lin, M.A. Nix, K.K. Leung, C. Kasap, E. Ramos, W.N. Vasquez, A. Talbot, M. Hale, A. Naik, A. Kishishita, P. Choudhry, A. Lopez-Girona, W. Miao, S.W. Wong, J.L. Wolf, T.G. Martin III, N. Shah, S. Vandenberg, S. Prakash, L. Besse, C. Driessen, A.D. Posey Jr., R.D. Mullins, J. Eyquem, J.A. Wells, A.P. Wiita. The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance. Nature Communications 13, 4121 (2022).
‍

W.A. Nyberg, J. Eyquem. Genome editing applications in cancer T cell therapy. Chapter in Genome Editing in Drug Discovery (2022).
‍

J. Mansilla-Soto*, J. Eyquem*, S. Haubner, M. Hamieh, J. Feucht, N. Paillon, A.E. Zucchetti, Z. Li, M. Sjöstrand, P.L. Lindenbergh, M. Saetersmoen, A. Dobrin, M. Maurin, A. Iyer, A.G. Angus, M.M. Miele, Z. Zhao, T. Giavridis, S.J.C. van der Stegen , F. Tamzalit, I. Rivière, M. Huse , R.C. Hendrickson, C. Hivroz, M. Sadelain. HLA-independent T cell receptors for targeting tumors with low antigen density. Nature Medicine 28, 345–352 (2022). *Equal contributions